Lilly expands manufacturing footprint in Ireland with $1.8 billion ...
网页INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.
Lilly.com | Eli Lilly and Company
网页INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug ... - CNN
网页2024年6月11日 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
All News - Eli Lilly and Company
网页Lilly's latest press releases, stories, news resources and more.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
网页2023年8月8日 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
News Release - Eli Lilly and Company
网页FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Eli Lilly (LLY) earnings Q2 2024 - CNBC
网页2024年8月8日 · That compares with a profit of $1.76 billion, or $1.95 a share, a year earlier. Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted ...
News Release - Eli Lilly and Company
网页2023年7月14日 · INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
网页2023年7月17日 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Next-generation drug from Eli Lilly boosts weight loss to 24% ... - CNN
网页2023年6月26日 · Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%.